The PDE5 inhibitor sildenafil improved the functional class and maximal aerobic capacity of pediatric PAH patients in the STARTS-1 trial, a double-blind, multicenter, placebo-controlled trial. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.